R3Mab, an antibody specifically acts on FGFR3 (IIIb and IIIc isoforms) but has no effect on FGFR1, FGFR2, or FGFR4 has been shown to exhibits significant inhibitory effects on FGF1-induced cancer cell proliferation and inhibitory effects on both bladder cancer and MM in mice [172]. Here, FGFR3 is linked to urinary bladder carcinoma.